Since 1923, we have been focused on innovation and leadership in diabetes care. Today we have a broad portfolio of medicines.
Since the launch of our first pen needle in 1985, we have been committed to enhancing injection experience by putting technology in patient hands.
Access information on our products for rare bleeding disorders, growth hormone-related disorders, and women's health.
Find information on our treatment for chronic weight management in adults who are overweight with one weight-related comorbidity or obesity.
The link above used in conjunction with the FDA-approved product labeling may be used to determine U.S. patents associated with the corresponding U.S. marketed product.
(Coagulation Factor VIIa [Recombinant])
Click here for NovoSeven® RT Prescribing Information
For Healthcare Professionals
(Coagulation Factor IX [Recombinant], GlycoPEGylated)
Click here for Rebinyn® Prescribing Information
[antihemophilic factor (recombinant), glycopegylated-exei]
Click here for Esperoct® Prescribing Information
(Antihemophilic Factor [Recombinant])
Click here for Novoeight® Prescribing Information
(Coagulation Factor XIII A-Subunit [Recombinant])
Click here for Tretten® Prescribing Information
(somatropin) injection 5 mg, 10 mg, 15 mg, 30 mg
Click here for Norditropin® Prescribing Information
(macimorelin) for oral solution
Click here for MacrilenTM Prescribing Information
(estradiol vaginal inserts) 10 mcg
Click here for Vagifem® Prescribing Information
©2019 Novo Nordisk. All rights reserved. US20ESP00010